CINECA IRIS Institutional Research Information System

VIGNA, Elisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.694
EU - Europa 1.350
AS - Asia 852
AF - Africa 8
OC - Oceania 7
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 4.922
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.667
CN - Cina 434
IT - Italia 409
SG - Singapore 245
IE - Irlanda 192
SE - Svezia 161
FR - Francia 128
UA - Ucraina 95
FI - Finlandia 88
GB - Regno Unito 69
DE - Germania 65
KR - Corea 50
VN - Vietnam 45
PL - Polonia 32
CA - Canada 27
ID - Indonesia 23
BE - Belgio 21
AT - Austria 20
CH - Svizzera 14
NL - Olanda 14
HK - Hong Kong 13
IN - India 13
JP - Giappone 12
ES - Italia 10
HU - Ungheria 7
RU - Federazione Russa 7
SN - Senegal 7
AU - Australia 5
EU - Europa 5
GR - Grecia 5
BR - Brasile 4
PK - Pakistan 3
PT - Portogallo 3
RO - Romania 3
TW - Taiwan 3
IR - Iran 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
AR - Argentina 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GE - Georgia 1
HR - Croazia 1
IL - Israele 1
LK - Sri Lanka 1
MO - Macao, regione amministrativa speciale della Cina 1
PH - Filippine 1
PY - Paraguay 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
TR - Turchia 1
Totale 4.922
Salva come PNG Salva come JPEG
Città #
Chandler 318
Beijing 276
Ann Arbor 262
Santa Clara 215
Dublin 191
Singapore 185
Fairfield 107
Ashburn 102
Dearborn 96
Houston 80
Torino 80
Wilmington 64
Turin 62
Woodbridge 60
Nyköping 59
Villeurbanne 57
Jacksonville 52
Medford 52
Cambridge 51
Columbus 49
Princeton 47
Seattle 46
Dong Ket 37
Milan 35
Guangzhou 28
Boston 26
Pisa 26
Fremont 24
Jakarta 23
Boardman 21
Warsaw 21
Redwood City 19
Shanghai 19
Vienna 19
Brussels 18
Helsinki 18
New York 16
San Diego 14
Toulouse 13
Hangzhou 12
Nanjing 12
Toronto 12
Rome 11
Buffalo 9
Los Angeles 9
Verona 9
Tokyo 8
Hefei 7
Palermo 7
Amsterdam 6
Basel 6
Lachine 6
Norwalk 6
Silver Spring 6
Upper Marlboro 6
Washington 6
Birmingham 5
Casalecchio di Reno 5
Florence 5
Luni 5
Rochester 5
Barcelona 4
Central 4
Dallas 4
Düsseldorf 4
Edinburgh 4
Kunming 4
London 4
Menlo Park 4
Mountain View 4
Munich 4
Nuremberg 4
Paris 4
San Francisco 4
Wroclaw 4
Zhengzhou 4
Abbiategrasso 3
Arlesheim 3
Auburn Hills 3
Boerne 3
Brescia 3
Budapest 3
Changsha 3
Chengdu 3
Cuneo 3
Cypress 3
Falkenstein 3
Hong Kong 3
Naples 3
Napoli 3
Nashville 3
Ottawa 3
Phoenix 3
San Mateo 3
Seoul 3
Southend 3
Sydney 3
Xian 3
Yangzhou 3
Alessandria 2
Totale 3.182
Salva come PNG Salva come JPEG
Nome #
Targeting the oncogenic Met receptor by antibodies and gene therapy. 233
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. 215
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. 193
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. 174
Quiescent neuronal progenitors are activated in the juvenile guinea pig lateral striatum and give rise to transient neurons 170
Rebound effects caused by withdrawal of MET Kinase inhibitor are quenched by a MET Therapeutic antibody 170
Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody 164
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells 157
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. 147
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. 141
MET/HGF co-targeting in pancreatic cancer: A tool to provide insight into the tumor/stroma crosstalk 138
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. 131
Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. 129
Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy 127
"Active" cancer immunotherapy by anti-Met antibody gene transfer 124
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 115
Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib 107
Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes 98
Mek1 inhibition in vivo mitigates progressive cardiac concentric hypertrophy promoted by activated Met receptor. 97
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours 97
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 96
The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation 93
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET 92
Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody 90
Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. 86
Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. 85
A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. 84
Hepatocyte growth factor is a regulator of monocyte-macrophage function 75
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers 74
Targeted anticancer therapy by a recombinant monovalent antibody against the MET oncogene 71
Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. 70
Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors 70
Antibody Fragments, Compositions And Uses Thereof - granted patent (USA) 69
Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor 67
MET overexpression turns human primary osteoblasts into osteosarcomas 66
TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR 65
Molecular engineering strategies tailoring the apoptotic response to a met therapeutic antibody 64
Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. 63
Hgf/met axis induces tumor secretion of tenascin-c and promotes stromal rewiring in pancreatic cancer 63
The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. 59
Semaphorin 3A normalizes the tumor vasculature and impairs tumor progression in a Nrp-1-independent manner 58
Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products 57
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. 57
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy 55
New antibody fragments, compositions and uses thereof 48
New Antibody Fragments, Compositions And Uses Thereof - granted patent (Eurasian Patent Organisation) 47
A receptor-antibody hybrid hampering MET-driven metastatic spread 47
Human cord blood CD34+ progenitor cells acquire functional cardiac properties through a cell fusion process. 46
New Antibody Fragments, Compositions And Uses Thereof - granted patent (Canada) 41
Anti-met fab-fc for the treatment of a tumor and/or metastasis 39
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma 32
Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination 25
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 24
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 20
MET Oncogene Targeting for Cancer Immunotherapy 20
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis 13
Totale 5.058
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.803
article - articoli 0
book - libri 0
conference - conferenze 1.002
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.805
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020255 0 0 0 0 0 0 69 39 43 52 31 21
2020/2021522 27 27 29 36 51 38 63 18 50 36 43 104
2021/2022824 58 53 45 76 24 47 36 29 25 56 263 112
2022/20231.002 71 83 19 78 106 246 70 92 126 20 64 27
2023/2024405 55 70 22 19 26 58 15 19 2 32 25 62
2024/2025732 14 102 80 107 317 110 2 0 0 0 0 0
Totale 5.058